The scientific team of Pulmobiotics, a company founded in 2020 at the Center for Genomic Regulation (CRG) in Barcelona, has started working on a 'living pill' to improve the efficacy of lung cancer treatment.
Pulmobiotics has raised €1.9M across 1 funding round from 1 investor, most recently a Seed round in Dec 2022. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-12-15 | Seed | €1.9M |
| European Innovation Council |
| View deal → |
